Welcome to our dedicated page for GRI Bio news (Ticker: GRI), a resource for investors and traders seeking the latest updates and insights on GRI Bio stock.
GRI Bio Inc (GRI) is a clinical-stage biotechnology pioneer advancing novel NKT cell-targeted therapies for inflammatory and autoimmune disorders. This dedicated news hub provides investors and industry stakeholders with essential updates on therapeutic developments, financial disclosures, and strategic milestones.
Access timely reports on GRI-0621 (oral inhibitor for liver disease/dermatology) and GRI-0803 (autoimmune candidate), including clinical trial progress, regulatory filings, and peer-reviewed research. Our curated collection features press releases, earnings call transcripts, and partnership announcements directly from the company and verified sources.
Key coverage areas include phase trial results, intellectual property updates, executive leadership changes, and scientific conference presentations. Bookmark this page to monitor GRI Bio's progress in developing oral therapies that modulate immune responses through its proprietary NKT cell platform.
GRI Bio, Inc. (NASDAQ: GRI) has appointed Leanne Kelly as Chief Financial Officer. With over 20 years of experience in finance, particularly in life sciences and technology, Kelly previously held the CFO role at Vallon Pharmaceuticals, which recently merged with GRI Bio. Her expertise in public and private markets was deemed essential as GRI transitions post-merger.
CEO Marc Hertz expressed confidence in Kelly's capabilities to strengthen the company's financial position and presence in the investment community. GRI Bio focuses on innovative therapies targeting inflammatory and autoimmune diseases, with promising developments like GRI-0621 for idiopathic pulmonary fibrosis.
FAQ
What is the current stock price of GRI Bio (GRI)?
What is the market cap of GRI Bio (GRI)?
